fm101
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 8, 2019 (NCT03879928)
Timeline
Indications
Mechanism of action
- Adenosine A3 receptorANTAGONIST
ADORA3 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04710524 | Phase 2 | Jun 10, 2021 | Future Medicine Ltd. |
| NCT04585100 | Phase 1/Phase 2 (Phase 2) | Oct 7, 2020 | Future Medicine Ltd. |
| NCT03879928 | Phase 1 | Jan 8, 2019 | Future Medicine Ltd., Pharmaceutical Research Associates, Inc. (PRA) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Future Medicine Ltd. | For profit | 3 | 3 | 2 | 2019 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1